晚期胃癌分子靶向与免疫治疗相关性研究

Research on the Correlation between Advanced Gastric Cancer Molecule Molecular Targeted and Immune Therapy

胃癌(gastric cancer, GC)是一种广泛存在于全球的恶性肿瘤,每年约有一千万到两千万的GC患者,其中以老年人居多,在我国,胃癌的发病率和死亡率均排在第二位。由于早期胃癌往往没有明显的临床表现,且患者缺乏相关的医学知识,对此并不了解,往往被忽略或者处理不当,大部分病人在发现时已是中、晚期,错过了最好的手术治疗时间。因此,GC已成为一个重要的临床问题,近年来,国内外的许多学者都致力于寻找新的诊断与治疗手段。对于中晚期胃癌患者,尽管化学疗法能提高病人的生命和生存质量,但是总体化疗效果不佳,不能保证长期生存。近年来,随着分子生物学技术的飞速发展,很多学者开发出了新的肿瘤靶向、免疫治疗药物,现对近几年来胃癌分子靶向与免疫治疗的现状和进展做一综述。

Gastric cancer (GC) is a kind of malignant tumor that exists widely worldwide. There are about 10 million to 20 million GC patients each year. Most of them are the elderly. In my country, the inci-dence and mortality of gastric cancer are ranked second. Because early gastric cancer often has no obvious clinical manifestations, and patients lack related medical knowledge, they do not under-stand this, and are often ignored or mishandled. Most patients were already in the middle and late stage when they discovered, and missed the best surgical treatment time. Therefore, GC has become an important clinical issue. In recent years, many scholars at home and abroad have been commit-ted to finding new diagnosis and treatment methods. For patients with gastric cancer in the middle and advanced periods, although chemotherapy can improve the quality of life and survival of pa-tients, the overall chemotherapy effect is not good and cannot guarantee long-term survival. In re-cent years, with the rapid development of molecular biology technology, many scholars have de-veloped new tumor-targeted and immunotherapy drugs. This article reviews the current status and progress of molecular targeted therapy and immunotherapy for gastric cancer in recent years.